Pharmaceutical News

RSS

AV drugs could help curb bacteria's growing resistance to antibiotic treatments

A new type of drug could help to combat growing antibiotic resistance, a study finds. Medicines that stop bacteria from harming their hosts, rather than kill them, could prevent bugs from evolving resistance to drug treatments, a review of research in the field suggests.

18 Mar 2014

Pierre Fabre Dermatologie receives FDA marketing authorization for pediatric drug Hemangeol

Pierre Fabre Dermatologie has obtained marketing authorization from the FDA for the pediatric drug Hemangeol (propranolol hydrochloride), which is the first and only approved treatment for "proliferating infantile hemangioma requiring systemic therapy".

18 Mar 2014

L. reuteri Protectis reduces diarrhea, respiratory tract infections in healthy children

Healthy children attending day-care centres have a significantly lower risk of getting diarrhoea or respiratory tract infections when given a daily supplement of Lactobacillus reuteri Protectis, a study in 336 children shows. "Our study confirms earlier published data in proving that preventive use of L. reuteri Protectis in healthy children reduces diarrhoeic episodes.

17 Mar 2014

Researchers create statistical model to predict whether heart scans are useful in prescribing statins

As long as inexpensive statins, which lower cholesterol, are readily available and patients don't mind taking them, it doesn't make sense to do a heart scan to measure how much plaque has built up in a patient's coronary arteries before prescribing the pills, according to a new study by researchers at UC San Francisco.

17 Mar 2014

Merck's NOXAFIL injection gets FDA approval for intravenous use

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use.

16 Mar 2014

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.

16 Mar 2014

PRP injections provide short- and long-term pain relief for patients with severe chronic hip bursitis

Chronic hip bursitis is a common yet difficult condition to treat successfully. A recent study, presented today at the 2014 Annual Meeting of the American Academy of Orthopaedic Surgeons, compared the results of PRP and cortisone injections in patients with severe chronic hip (greater trochanteric) bursitis.

14 Mar 2014

Researcher discover new chemical class that attacks two key cancer cell building block targets

Imagine cutting down the growth of cancer cells at their earliest stages to halt tumor growth. Research conducted by leading cancer metabolism researchers at Stony Brook University, Paul M. Bingham, PhD, and Zuzana Zachar, PhD, is showing promise in this approach with their clinical investigation of a new class of compounds that disrupt cancer cell mitochondrial metabolism.

14 Mar 2014

TFDA approves TaiGen's Taigexyn NDA for treatment of community-acquired bacterial pneumonia

TaiGen Biotechnology Company, Limited today announced that the Taiwan Food and Drug Administration has approved the new drug application (NDA) of Taigexyn (nemonoxacin) oral formulation (500 mg) for the treatment of community-acquired bacterial pneumonia (CAP). With this NDA approval, Taiwan is the first region to grant marketing approval to Taigexyn.

13 Mar 2014

Knopp and NIAID collaborate to investigate eosinophil-lowering effects of dexpramipexole

Knopp Biosciences LLC today announced a second collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to investigate the eosinophil-lowering effects of the investigational drug dexpramipexole.

13 Mar 2014

Investigators urge drug regulators to provide clear evidence on statins’ side effects

At a time when the wider prescription of statins is under renewed public scrutiny, a substantial analysis of placebo-controlled randomised trials of statins has found that only a small minority of side effects reported by those taking the cholesterol-lowering drugs are actually attributable to them.

13 Mar 2014

Two synergistic therapies allow solid tumors to act as their own cancer-fighting vaccine

Researchers in the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute eradicated solid tumors in laboratory mice using a novel combination of two targeted agents. These two synergistic therapies stimulate an immune response, ultimately allowing solid tumors to act as their own cancer-fighting vaccine.

13 Mar 2014

Perrigo launches methazolamide tablets

Perrigo Company today announced that it has launched, through a distribution and supply agreement, methazolamide tablets, the generic equivalent to Neptazane tablets. This product is a component of the contingent rights Perrigo received in connection with its acquisition of a portfolio of ophthalmic products from Fera Pharmaceuticals, LLC and its affiliates in June of last year.

12 Mar 2014

EPFL sets up foundation to release antibiotic for tuberculosis

Even though tuberculosis kills more than 1.5 million people every year, the market is not cost-effective for pharmaceutical companies. So EPFL is setting up a foundation to release an antibiotic developed in its own laboratories under EU funding.

12 Mar 2014

CPhI to conduct the 4th NEXTGEN China 2014 Conference from March 27 to 28

In March 2012, the 1st Nextgen China was held successfully in Shanghai. FDA, USP, national institutes for Food and Drug Control and leading pharmaceutical companies from home and abroad were invited to give presentations.

12 Mar 2014

Experimental drugs offer hope for people with hepatitis C

Patrizia Cazzaniga had heard the horror stories about early treatments for hepatitis C - multiple daily pills and weekly shots for up to a year, side effects that could be debilitating, and a cure rate of only about 40 percent.

11 Mar 2014

MedVantx MedStart Connect program increases patient initiation of new prescriptions

New research presented today at the World Congress Summit to Improve Adherence and Enhance Patient Engagement by researchers from the University of Pittsburgh School of Pharmacy, finds that a unique generic medication sampling program, the MedVantx MedStart™ Connect program, implemented in the primary care physicians' office, led to significantly increased patient initiation of new prescriptions (primary adherence) as well as continued use of the medications (secondary adherence), and could possibly lead to savings for health plans.

11 Mar 2014

"Doctor shopping" results in increased drug use among postoperative orthopaedic trauma patients

"Doctor shopping," the growing practice of obtaining narcotic prescriptions from multiple providers, has led to measurable increases in drug use among postoperative orthopaedic trauma patients, according to a new study presented today at the 2014 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS).

11 Mar 2014

AAOHN, ACOEM collaborate to study workplace health and safety issues linked with use of marijuana

The American Association of Occupational Health Nurses (AAOHN) and the American College of Occupational and Environmental Medicine (ACOEM) have announced they will collaborate to study workplace health and safety issues associated with worker impairment from the use of marijuana and other drugs.

11 Mar 2014

Statins combined with conventional blood clot prevention therapies, reduce VTE risk by 48%

Statins have long been known to lower cholesterol and, more recently, to decrease the risk of deep vein thrombosis (blood clots) in healthy, non-surgical patients.

11 Mar 2014

Pharmaceutical News

AV drugs could help curb bacteria's growing resistance to antibiotic treatments

Pierre Fabre Dermatologie receives FDA marketing authorization for pediatric drug Hemangeol

L. reuteri Protectis reduces diarrhea, respiratory tract infections in healthy children

Researchers create statistical model to predict whether heart scans are useful in prescribing statins

Merck's NOXAFIL injection gets FDA approval for intravenous use

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

PRP injections provide short- and long-term pain relief for patients with severe chronic hip bursitis

Researcher discover new chemical class that attacks two key cancer cell building block targets

TFDA approves TaiGen's Taigexyn NDA for treatment of community-acquired bacterial pneumonia

Knopp and NIAID collaborate to investigate eosinophil-lowering effects of dexpramipexole

Investigators urge drug regulators to provide clear evidence on statins’ side effects

Two synergistic therapies allow solid tumors to act as their own cancer-fighting vaccine

Perrigo launches methazolamide tablets

EPFL sets up foundation to release antibiotic for tuberculosis

CPhI to conduct the 4th NEXTGEN China 2014 Conference from March 27 to 28

Experimental drugs offer hope for people with hepatitis C

MedVantx MedStart Connect program increases patient initiation of new prescriptions

"Doctor shopping" results in increased drug use among postoperative orthopaedic trauma patients

AAOHN, ACOEM collaborate to study workplace health and safety issues linked with use of marijuana

Statins combined with conventional blood clot prevention therapies, reduce VTE risk by 48%

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News